Literature DB >> 7653531

Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD.

J Du1, P D Wilson.   

Abstract

The underlying mechanism of the hyperproliferative response of human autosomal dominant polycystic kidney disease (ADPKD) epithelia was studied. Epidermal growth factor (EGF) protein is highly expressed in ADPKD cyst epithelia in vivo, and primary cultures are hyperesponsive to mitogenic stimulation by EGF in vitro. Doses of > 1 ng/ml EGF were highly mitogenic to ADPKD epithelia. 3H-labeled thymidine proliferation assays showed that cyst fluids and ADPKD epithelial cell-conditioned media also stimulated renal epithelial cell proliferation and contained EGF immunoreactivity (6, 30, and 37 kDa) as detected by Western blots. Radioimmunoassays detected mean levels of 2.87 and 1.4 ng/ml EGF in cyst fluids from early (proliferative) and end-stage ADPKD cysts, respectively. Scatchard analysis of 125I-labeled EGF binding to apical and basolateral membrane showed high-affinity binding to basolateral membranes of normal and ADPKD kidneys but additional unique high-affinity receptor binding to apical membranes of ADPKD but not normal kidneys. Cross-linking analysis and antiphosphotyrosine Western analysis demonstrated functionally active apical EGF receptors at 150-170 kDa. These results suggest mediation of cyst expansion via an autocrine loop involving EGF synthesis and processing by cyst epithelial cells, apical secretion into cyst lumens, and subsequent binding to and phosphorylation of apical membrane EGF receptors. These findings are consistent with a membrane protein polarization defect in ADPKD cyst epithelia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7653531     DOI: 10.1152/ajpcell.1995.269.2.C487

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  56 in total

1.  ErbB4 modulates tubular cell polarity and lumen diameter during kidney development.

Authors:  Ville Veikkolainen; Florence Naillat; Antti Railo; Lijun Chi; Aki Manninen; Peter Hohenstein; Nick Hastie; Seppo Vainio; Klaus Elenius
Journal:  J Am Soc Nephrol       Date:  2011-11-10       Impact factor: 10.121

Review 2.  Epigenetics and autosomal dominant polycystic kidney disease.

Authors:  Xiaogang Li
Journal:  Biochim Biophys Acta       Date:  2010-10-20

Review 3.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  ADPKD: molecular characterization and quest for treatment.

Authors:  Shigeo Horie
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

Review 5.  Ciliary dysfunction in polycystic kidney disease: an emerging model with polarizing potential.

Authors:  Robert J Kolb; Surya M Nauli
Journal:  Front Biosci       Date:  2008-05-01

6.  Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2.

Authors:  L Tsiokas; E Kim; T Arnould; V P Sukhatme; G Walz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

Review 7.  Cell-Cell Contact and Receptor Tyrosine Kinase Signaling.

Authors:  Christine Chiasson-MacKenzie; Andrea I McClatchey
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 8.  Regulation of transport in the connecting tubule and cortical collecting duct.

Authors:  Alexander Staruschenko
Journal:  Compr Physiol       Date:  2012-04       Impact factor: 9.090

9.  Src inhibition ameliorates polycystic kidney disease.

Authors:  William E Sweeney; Rodo O von Vigier; Philip Frost; Ellis D Avner
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

10.  Homophilic and heterophilic polycystin 1 interactions regulate E-cadherin recruitment and junction assembly in MDCK cells.

Authors:  Andrew J Streets; Bart E Wagner; Peter C Harris; Christopher J Ward; Albert C M Ong
Journal:  J Cell Sci       Date:  2009-04-07       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.